Recruiting

Testing a new bleeding treatment for severe hemophilia A

Plain-English translation of NCT07663903 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , a new medication designed to help people with severe hemophilia A stop bleeding when it occurs. Hemophilia A is a genetic bleeding disorder where the body doesn't make enough of a protein called factor VIII, which helps blood clot. This study will measure how well and safely this new treatment works when used on-demand to treat bleeding episodes.

People with severe hemophilia A struggle with unexpected bleeding that can be serious and limit their daily lives. Researchers want to see if this medication can effectively stop bleeding when it happens and whether it's safe to use long-term.

Do you qualify?

You likely qualify if…

you are male, between age 12 and 65 years old
you have been clinically diagnosed with severe hemophilia A (factor VIII activity less than 1%)
you have previously received factor VIII treatment at least 150 times before
you have fully understood the study details and signed a consent form, and your parents or guardian (if under 18) can support your participation

You likely don't qualify if…

you have a known allergy to the medication or its ingredients, including mouse or hamster proteins
you have a history of developing antibodies against factor VIII (called inhibitors) or have a family history of this
you have severe liver or kidney problems shown by recent blood tests
you are taking blood-thinning medications (anticoagulants) or certain anti-inflammatory drugs that you cannot stop
you have HIV, hepatitis C, or other active infections, or a serious heart condition

What participation looks like

You will receive the medication as an injection when you have bleeding episodes that need treatment, using doses between 20–50 units per kilogram of your body weight. The study will involve multiple clinic visits where doctors will check how well the treatment works, monitor your blood work and overall safety, and watch for any side effects. You'll also provide blood samples so researchers can study how the medication works in your body and check whether your immune system reacts to it.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Testing a new bleeding treatment for severe hemophilia A

What is this trial?

Do you qualify?

What participation looks like

Trial locations(24 sites)